Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): a prospective cohort study (Journal of Infection, 2025)

(untitled) - Feng, S; Bibi, S; Aley, PK; Cappuccini, F; Clutterbuck, EA; Conlin, K; Ebrahimi, N; Eordogh, A; Faust, SN; Felle, S; Green, J; Gill, H; et al.